136 related articles for article (PubMed ID: 12014617)
1. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.
De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M
Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells.
Bowen D; Southerland WM; Hawkins M; Johnson DH
Anticancer Res; 2000; 20(3A):1415-7. PubMed ID: 10928050
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
Fryar-Tita EB; Das JR; Davis JH; Desoto JA; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(3B):1393-9. PubMed ID: 17595753
[TBL] [Abstract][Full Text] [Related]
6. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
7. The interaction of the steroidal antagonist faslodex and methotrexate.
DeSoto JA; Bowen D; Southerland WM; Hawkins M; Fryar EB; Davis JH
Cell Mol Biol (Noisy-le-grand); 2003 Nov; 49(7):1067-9. PubMed ID: 14682388
[TBL] [Abstract][Full Text] [Related]
8. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
[TBL] [Abstract][Full Text] [Related]
9. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
10. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
11. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
Das JR; Fryar EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642
[TBL] [Abstract][Full Text] [Related]
13. Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells.
Wołczynski S; Surazyński A; Swiatecka J; Pałka J
Gynecol Endocrinol; 2001 Jun; 15(3):225-33. PubMed ID: 11447735
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
15. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
[TBL] [Abstract][Full Text] [Related]
16. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.
Gao ZO; Gao ZP; Fields JZ; Boman BM
Anticancer Res; 2002; 22(3):1379-83. PubMed ID: 12168814
[TBL] [Abstract][Full Text] [Related]
17. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Capizzi RL
Cancer Treat Rep; 1981; 65 Suppl 4():115-21. PubMed ID: 7049375
[TBL] [Abstract][Full Text] [Related]
18. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320
[TBL] [Abstract][Full Text] [Related]
19. Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells.
Schultz RM; Dempsey JA
Anticancer Res; 2001; 21(5):3209-14. PubMed ID: 11848474
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim IY; Seong DH; Kim BC; Lee DK; Remaley AT; Leach F; Morton RA; Kim SJ
Cancer Res; 2002 Jul; 62(13):3649-53. PubMed ID: 12097269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
